Bayer commences study of symptomatic uterine fibroid therapy

Bayer has announced the commencement of a phase III clinical trial assessing the potential benefits of a new treatment for symptomatic uterine fibroids.

The first trial patient has been enrolled in the phase III clinical study program ASTEROID, which will investigate the oral selective progesterone receptor modulator vilaprisan in women suffering from uterine fibroids.

Vilaprisan functions through a process known as progesterone receptor modulation, which may facilitate the long-term treatment of uterine fibroids and endometriosis. The new study will assess its effect on heavy menstrual bleeding, reduction in fibroid size and improvement in quality of life.

This study programme will include several trials and aims to enrol more than 3,600 patients at around 900 centres in approximately 40 countries. It is anticipated that it will take three years to complete the programme.

Dr Joerg Moeller, member of the executive committee of Bayer's pharmaceutical division and head of development, said: "It is our ambitious goal that our research efforts in this field result in a medical therapy that controls symptoms and thereby significantly improves the quality of life for women with uterine fibroids."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.